Literature DB >> 10073286

The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.

J Tsihlias1, L Kapusta, J Slingerland.   

Abstract

Progression through the cell cycle is governed by cyclin-dependent kinases (cdks), whose activity is inhibited by the cdk inhibitors. Cyclins, cdks, and cdk inhibitors are frequently deregulated in cancers. This chapter reviews the prognostic significance of alterations in cdk inhibitors. Loss of p27 protein provides independent prognostic information in breast, prostate, colon, and gastric carcinomas, and immunohistochemical (IHC) staining for p27 may eventually become part of routine histopathologic processing of cancers. Loss of IHC staining for p21 may be prognostic in certain cancers but conflicting results are reported in breast cancer. Reports on homozygous deletion of p16 and p15 genes suggest the value of larger, prospective studies with standardized treatment protocols to definitively establish the prognostic utility of p15/p16 deletions in acute leukemias. Larger trials and the development of a consensus on methods for deletion analysis, IHC staining, and tumor scoring will be needed to move these molecular assays from bench to bedside.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073286     DOI: 10.1146/annurev.med.50.1.401

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  71 in total

1.  The kinetic origins of the restriction point in the mammalian cell cycle.

Authors:  B D Aguda; Y Tang
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

Review 2.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

3.  XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

Authors:  Jui Pandhare-Dash; Chinmay K Mantri; Yuanying Gong; Zhenbang Chen; Chandravanu Dash
Journal:  Prostate       Date:  2011-09-19       Impact factor: 4.104

4.  Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase.

Authors:  Kui Xu; Charles Belunis; Wei Chu; David Weber; Frank Podlaski; Kuo-Sen Huang; Steven I Reed; Lyubomir T Vassilev
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

Review 5.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

6.  Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate.

Authors:  David R Shaffer; Agnes Viale; Ryota Ishiwata; Margaret Leversha; Semra Olgac; Katia Manova; Jaya Satagopan; Howard Scher; Andrew Koff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

7.  p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.

Authors:  Srirupa Roy; Mallikarjuna Gu; Kumaraguruparan Ramasamy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert A Sclafani; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.

Authors:  Amer M Mirza; Stephan Gysin; Nisar Malek; Kei-ichi Nakayama; James M Roberts; Martin McMahon
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest.

Authors:  Avudaiappan Maran; Kristen L Shogren; Michaela Benedikt; Gobinda Sarkar; Russell T Turner; Michael J Yaszemski
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

10.  p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma.

Authors:  Yiting Li; Manjula Nakka; Aaron J Kelly; Ching C Lau; Mark Krailo; Donald A Barkauskas; John M Hicks; Tsz-Kwong Man
Journal:  Cancer Res       Date:  2016-04-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.